Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival - PubMed (original) (raw)
Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival
Hongkui Jin et al. Cancer Res. 2004.
Abstract
Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) is a tumor necrosis factor superfamily member that induces apoptosis through the death receptors DR4 and/or DR5 in various cancer cell types but not in most normal cells. Several lung cancer cell lines express DR4 and DR5 and undergo apoptosis in vitro in response to Apo2L/TRAIL. We investigated the efficacy of recombinant soluble human Apo2L/TRAIL and its interaction with chemotherapy in xenograft models based on human NCI-H460 non-small cell lung carcinoma cells. In vitro, Taxol enhanced caspase activation and apoptosis induction by Apo2L/TRAIL. In vivo, Apo2L/TRAIL or Taxol plus carboplatin chemotherapy partially delayed progression of established subcutaneous tumor xenografts, whereas combined treatment caused tumor regression and a substantially longer growth delay. Apo2L/TRAIL, chemotherapy, or the combination of both inhibited growth of preformed orthotopic lung parenchymal tumors versus control by 60%, 57%, or 97%, respectively (all P < 0.01; n = 8-10). Furthermore, combination treatment improved day-90 survival relative to control (7 of 15 versus 1 of 15; P = 0.0003 by Mantel-Cox) as well as to Apo2L/TRAIL (3 of 14; P = 0.031) or chemotherapy (3 of 15; P = 0.035). These studies provide evidence for in vivo activity of Apo2L/TRAIL against lung tumor xenografts and underscore the potential of this ligand for advancing current lung cancer treatment strategies.
Similar articles
- Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5.
Frese S, Frese-Schaper M, Andres AC, Miescher D, Zumkehr B, Schmid RA. Frese S, et al. Cancer Res. 2006 Jun 1;66(11):5867-74. doi: 10.1158/0008-5472.CAN-05-3544. Cancer Res. 2006. PMID: 16740726 - Apo2l/Tumor necrosis factor-related apoptosis-inducing ligand prevents breast cancer-induced bone destruction in a mouse model.
Thai le M, Labrinidis A, Hay S, Liapis V, Bouralexis S, Welldon K, Coventry BJ, Findlay DM, Evdokiou A. Thai le M, et al. Cancer Res. 2006 May 15;66(10):5363-70. doi: 10.1158/0008-5472.CAN-05-4386. Cancer Res. 2006. PMID: 16707463 - The potential of the tumor microenvironment to influence Apo2L/TRAIL induced apoptosis.
Mace TA, Yamane N, Cheng J, Hylander BL, Repasky EA. Mace TA, et al. Immunol Invest. 2006;35(3-4):279-96. doi: 10.1080/08820130600745463. Immunol Invest. 2006. PMID: 16916755 Review. - Targeting death receptors in cancer with Apo2L/TRAIL.
Kelley SK, Ashkenazi A. Kelley SK, et al. Curr Opin Pharmacol. 2004 Aug;4(4):333-9. doi: 10.1016/j.coph.2004.02.006. Curr Opin Pharmacol. 2004. PMID: 15251125 Review.
Cited by
- Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces death receptor 5 networks that are highly organized.
Valley CC, Lewis AK, Mudaliar DJ, Perlmutter JD, Braun AR, Karim CB, Thomas DD, Brody JR, Sachs JN. Valley CC, et al. J Biol Chem. 2012 Jun 15;287(25):21265-78. doi: 10.1074/jbc.M111.306480. Epub 2012 Apr 10. J Biol Chem. 2012. PMID: 22496450 Free PMC article. - Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer.
Loebinger MR, Eddaoudi A, Davies D, Janes SM. Loebinger MR, et al. Cancer Res. 2009 May 15;69(10):4134-42. doi: 10.1158/0008-5472.CAN-08-4698. Epub 2009 May 12. Cancer Res. 2009. PMID: 19435900 Free PMC article. - TRAIL induces apoptosis in oral squamous carcinoma cells--a crosstalk with oncogenic Ras regulated cell surface expression of death receptor 5.
Chen JJ, Mikelis CM, Zhang Y, Gutkind JS, Zhang B. Chen JJ, et al. Oncotarget. 2013 Feb;4(2):206-17. doi: 10.18632/oncotarget.813. Oncotarget. 2013. PMID: 23470485 Free PMC article. - Anti-idiotype antibody induced cellular immunity in mice transgenic for human carcinoembryonic antigen.
Saha A, Chatterjee SK, Foon KA, Bhattacharya-Chatterjee M. Saha A, et al. Immunology. 2006 Aug;118(4):483-96. doi: 10.1111/j.1365-2567.2006.02391.x. Immunology. 2006. PMID: 16895556 Free PMC article. - Combined modality therapy with TRAIL or agonistic death receptor antibodies.
Amm HM, Oliver PG, Lee CH, Li Y, Buchsbaum DJ. Amm HM, et al. Cancer Biol Ther. 2011 Mar 1;11(5):431-49. doi: 10.4161/cbt.11.5.14671. Epub 2011 Mar 1. Cancer Biol Ther. 2011. PMID: 21263219 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical